Baby Gender

Baby Gender helps your patients achieve their family balancing goals.

Baby Gender
Benefits
Indications

What is Baby Gender test?

Baby Gender test is used alongside in-vitro fertilization (IVF) to screen 5 most common abnormalities in embryos that is chromosome 21, 18, 13, X and Y.
The abnormalities are identified as chromosome 21 – Down Syndrome, 18 – Edwards Syndrome, 13 – Patau Syndrome.
The information obtained also provides the details of the gender of the embryo prior to transfer to help couples fulfil their family planning desires.

What is the procedure?

Why use Baby Gender test?

We use the most advanced technology, NGS (Next-Generation Sequencing) to perform the Baby Gender test:

Rapid technology allowing embryos to be transferred in fresh (Day 3 embryos)
Our technology and experience allows to analyze 5 most critical chromosomes 21, 18, 13, X and Y in a 12-hour procedure which provides results in more than 99% of cases.
Most accurate determination of gender of the embryos along with higher pregnancy success rate as it eradicates the leading cause of the IVF Failure (chromosomal abnormality)

Who should use Baby Gender test?

It is indicated for couples who want to have a baby of a particular gender
Female patients over age 35
Patients interested in selecting the best embryo for an elective Single Embryo Transfer or SET and avoid multiple pregnancies
Patients who already have a child with a chromosomal abnormality or had a previous pregnancy with a chromosomal abnormality issue

Specialists’ documents

Step Guide

Download

Brochure

Download

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility doctors worldwide we investigate human reproduction to change the lives of couples who are trying to conceive.

Learn more about Igenomix

Other services you may be interested

PGT-A

Chromosomally normal
embryos selection

More information

ERA

Evaluates the endometrial receptivity

More Information

EndomeTRIO

A new dimension of endometrial health

More information

Igenomix is in the media

IGENOMIX has not affiliated any news outlet or publication identified above. News coverage does not constitute an endorsement of IGENOMIX or its products

Gender selection and a complete analysis of most critical chromosomal abnormalities.

24-hour reporting using advanced NGS technology

Result is 99% accurate

CAP Accreditated

Are you interested?